Selective Sphingosine 1-Phosphate Receptor 1 Modulation Augments Thrombolysis of Low-Dose Tissue Plasminogen Activator Following Cerebrovascular Thrombosis.

Front Immunol · 2022 · PMC9198651 · PMID 35720286

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Consistent with our recent study showing that a selective S1PR1 modulator RP101075, a metabolite of ozanimod, led to improved flow velocity following arteriole thrombosis induced by laser-irradiation ( 13 ), the present study has demonstrated that the addition of ozanimod to subthrombolytic dose of tPA results in a highly significant improvement of flow velocity at least until 90 min after treatment.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.